Compare Sana Biotechnology Inc (SANA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Teradyne, Inc. — how do they compare? Sana Biotechnology Inc trades at $3.19 (market cap $947.48M), while Teradyne, Inc. trades at $378 (market cap $59.99B). The key difference: Teradyne, Inc. is far larger — about 63.3× Sana Biotechnology Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TER | |
|---|---|---|
Market Cap | $947.48M | $59.99B |
Sector | Health | Technology |
52-Week High | $5.92 | $483.84 |
52-Week Low | $2.68 | $112.24 |
Enterprise Value | $860.73M | $59.73B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
Teradyne (TER) trades at $372.06, up 4.21% in the last session, with a bullish technical signal and strong institutional interest. The stock shows robust fundamentals, including a 59.24% gross margin and consistent earnings beats, with Q3 2026 EPS expected at $2.03. Recent news highlights AI-driven demand for UltraFLEXplus systems, positioning TER for growth in semiconductor testing.
Outlook is positive with a $474.78 analyst price target implying 28% upside, supported by AI and data center expansion. Risks include reliance on tech cycles and competitive pressures from KLA and Cohu. Cash flow trends show improvement, with net cash flow projected to turn positive in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
